SAP-001 is viewed as a novel clinical stage agent with disease modification potential for gout patientswith highly safe, efficacious, well-tolerated and easily administered. SAP-001could be used in patients unable to control their gout with allopurinol.SAP-001 cansignificant reduce uric acid /eliminate the risk of acute gout attack/reduce and/or eliminate tophi.

Over time, focus on gaining acceptance for SAP-001 to be 1st line treatment for Gout, as well as for Gout patients that are not well controlled on allopurinol and/or febuxostat in addition to refractory/tophaceous Gout patients.

Sizeable market potential with $1B+ potential for Gout in US alone.